Alemtuzumab (Campath) Off-Label for Relapsing Multiple Sclerosis
Alemtuzumab (Campath), a genetically engineered, humanized monoclonal antibody currently approved to treat B-cell chronic lymphocytic leukemia (BCLL) and used off-label for induction therapy in solid organ transplants, is now also being tried off-label for treatment of relapsing multiple sclerosis (MS)....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Alemtuzumab (Campath) Off-Label for Relapsing Multiple Sclerosis
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1307
Article Code: 1307a
Date: March 9, 2009
Volume: 51
Pages: 17-18
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1307
Article Code: 1307a
Date: March 9, 2009
Volume: 51
Pages: 17-18
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)